Study Overview

Evaluation of a single IV dose of the investigational drug, Oritavancin, in children.

Study Eligibility

Children less than 18 years of age hospitalized and receiving antibiotic therapy for suspected or confirmed Gram-positive bacterial infections.

Content Study Link


For more information about this study, contact Robin Gibson, RN, Study Coordinator, at 501-364-1542.